What is the need for comparative effectiveness studies in IBD?

被引：2
|
作者：
Flasar, Mark H. [1 ]
Cross, Raymond K. [1 ]
机构：
[1] Univ Maryland, Sch Med, Div Gastroenterol & Hepatol, Baltimore, MD 21201 USA
来源：
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY | 2014年 / 8卷 / 08期
关键词：
comparative effectiveness research; Crohn's disease; inflammatory bowel disease; ulcerative colitis; EARLY COMBINED IMMUNOSUPPRESSION; CROHNS-DISEASE; INFLIXIMAB; THERAPY; MAINTENANCE; COMBINATION; MANAGEMENT;
D O I：
10.1586/17474124.2014.945916
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Unlike traditional clinical trial research, Comparative Effectiveness Research seeks to determine what is 'best' for a typical patient when deciding between effective options used in daily practice - a therapy, diagnostic test, or course of action. There is a clear need for Comparative Effectiveness Research in Inflammatory Bowel Disease, a point emphasized by the Institute of Medicine and supported by governmental agencies and escalating funding. This review highlights the rationale and support for Comparative Effectiveness Research, provides examples of Comparative Effectiveness Research in Inflammatory Bowel Disease, and outlines current and future focus for Comparative Effectiveness Research in Inflammatory Bowel Disease.
引用
收藏
页码：851 / 854
页数：4
相关论文
共 50 条
12345